Takeda signs deal with UK biotech GammaDelta Therapeutics on T cell therapy
The Japanese pharma company, led by chief executive Christophe Weber, is looking to upgrade its R&D pipeline with some of the best cutting-edge science, and is investing in the newly launched biotech as part of this strategy.